



TITLE: Sex selection drug and congenital malformations in North India

Name: Chinmayee Panda

Affiliation: State programme lead, Centre for Stem cell research, CMC Vellore

Country: India

Email ID: Chinmayeepgi88@gmail.com

ABSTRACT (upto 300 words)

Background: An increasing incidence of congenital malformations (CMF) has been reported in North India in cases use of traditional drug by Mothers to have male child. Aim was to ascertain the association of Sex selection drug (SSD) and congenital malformations. **Methods:** This hospital-based age-sex matched pair case control study was done at Advanced Pediatric Centre, Obstetrics and Gynaecology department (ANC clinic, Maternity ward, labor room etc.) and Special Clinics, PGIMER, Chandigarh, India in 2019. The mothers were interviewed to collect information about risk factors. **Results:** Two hundred three CMF (under five children and gestational CMF) cases and same number of controls were studied. Significant association of CMF was observed with the use of sex selection drugs by mothers (OR= 4.35). **Conclusions:** The use of sex selection drugs is an avoidable risk factor of CMF and is of high public health importance. People need to be educated about this. **Keywords:** Antenatal care, Child health, Congenital malformations, Reproductive health, Sex selection.

BIOGRAPHY (upto 200 words)

Dr Chinmayee Panda has completed her MPH from PGIMER, Chandigarh and Fellowship in Obstetrics and Gynaecology by Medigrad with electronic foetal monitoring from Royal college of London. MBBS from MKCG MCH, Berhampur University, India. She is State Programme Lead, Control of Thalassaemia and sickle cell disease in Odisha, Centre for stem cell research, CMC Vellore; continuing PHD in School of Public Health, KIIT university. She is a ToT of various national health programmes and worked in international organisations like UNDP, UNFPA. She has many a international book and journal publications.

Presenter Name: Chinmayee Panda.

Mode of Presentation: Webinar Oral

Contact number: +91 7978085592, wats ap 9437463771

